Author:
Ferdinandi Eckhardt S.,Vassilakos Aikaterini,Lee Yoon,Lightfoot Jeff,Fitsialos Dimitri,Wright Jim A.,Young Aiping H.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference34 articles.
1. Hurta RA, Wright JA (1992) Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem 267:7066–7071
2. Reichard P (1993) From RNA to DNA, why so many ribonucleotide reductases? Science 260:1773–1777
3. Lewis WH, Kuzik BA, Wright JA (1978) Assay of ribonucleotide reduction in nucleotide-permeable hamster cells. J Cell Physiol 94:287–298
4. Fan H, Villegas C, Wright JA (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93:14036–14040
5. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802–2811
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献